Literature DB >> 3247313

Dextromethorphan pretreatment induces antipyrine clearance in the rat.

C K Svensson1, J A Ware.   

Abstract

Numerous agents that undergo extensive first-pass metabolism have been shown to inhibit oxidative drug metabolism. To examine whether this effect is related to the chemical structure or pharmacokinetic characteristics of the inhibiting agent, we determined the effect of dextromethorphan (a compound which exhibits pharmacokinetic similarities to, but is chemically dissimilar from, previously studied agents) on the disposition of antipyrine. A single oral dose of dextromethorphan hydrobromide, 100 mg/kg, 1 hr prior to antipyrine administration had no significant effect on the pharmacokinetics of this model substrate. The administration of dextromethorphan at the same dose twice daily for 3 days and an additional dose 1 hr prior to antipyrine administration resulted in a 33% increase in the clearance of antipyrine. These data indicate that dextromethorphan is capable of inducing hepatic microsomal enzymes. Studies are needed to determine if this effect also occurs upon chronic administration in humans. These data suggest that the pharmacokinetic characteristic of extensive first-pass metabolism is not necessarily associated with inhibition of drug metabolism.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3247313     DOI: 10.1023/a:1015940518439

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  23 in total

1.  INHIBITION OF HEXOBARBITAL METABOLISM BY ETHYLMORPHINE AND CODEINE IN THE INTACT RAT.

Authors:  A RUBIN; T R TEPHYL; G J MANNERING
Journal:  Biochem Pharmacol       Date:  1964-07       Impact factor: 5.858

2.  CHRONIC INTRAVENOUS CANNULAS FOR RATS.

Authors:  J R WEEKS; J D DAVIS
Journal:  J Appl Physiol       Date:  1964-05       Impact factor: 3.531

3.  Co-inheritance of the polymorphic metabolism of encainide and debrisoquin.

Authors:  R L Woosley; D M Roden; G H Dai; T Wang; D Altenbern; J Oates; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1986-03       Impact factor: 6.875

Review 4.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

5.  The urinary excretion of dextromethorphan and three metabolites in dogs and humans.

Authors:  J W Barnhart
Journal:  Toxicol Appl Pharmacol       Date:  1980-08       Impact factor: 4.219

6.  Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.

Authors:  B Schmid; J Bircher; R Preisig; A Küpfer
Journal:  Clin Pharmacol Ther       Date:  1985-12       Impact factor: 6.875

7.  Dextromethorphan: radioimmunoassay and pharmacokinetics in the dog.

Authors:  R Dixon; J J Carbone; E Mohacsi; C Perry
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1978-11

8.  Comparison of the antitussive effects of codeine phosphate 20 mg, dextromethorphan 30 mg and noscapine 30 mg using citric acid-induced cough in normal subjects.

Authors:  D W Empey; L A Laitinen; G A Young; C E Bye; D T Hughes
Journal:  Eur J Clin Pharmacol       Date:  1979       Impact factor: 2.953

9.  Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.

Authors:  L A Siddoway; K A Thompson; C B McAllister; T Wang; G R Wilkinson; D M Roden; R L Woosley
Journal:  Circulation       Date:  1987-04       Impact factor: 29.690

10.  Effect of butalbital and phenobarbital pretreatment on antipyrine clearance in the rat.

Authors:  F L Tse; T Chang; J M Jaffe
Journal:  Arch Int Pharmacodyn Ther       Date:  1986-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.